US-based clinical-stage biotechnology firm Advaxis has begun enrolment and dosing in its Phase III clinical trial (AIM2CERV) of axalimogene filolisbac for the treatment of patients with advanced stage cervical cancer.

Axalimogene filolisbac is an immunotherapy product developed using a live attenuated Listeria monocytogenes (Lm), which is bioengineered to produce an HPV-16 E7 protein fused with a truncated fragment of listeriolysin O (tLLO).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug is designed to target the HPV transformed cells for triggering anti-tumour T-cell immunity and destroying immune tolerance in the tumour microenvironment.

The global, randomised Phase III trial will evaluate axalimogene filolisbac as an adjuvant therapy in patients with high-risk, locally advanced carcinoma of the cervix (HRLACC), after primary treatment with chemotherapy and radiation.

"The drug is designed to target the HPV transformed cells for triggering anti-tumour T-cell immunity and destroying immune tolerance in the tumour microenvironment."

The trial will assess the primary objective of disease-free survival (DFS) along with secondary objectives such as overall survival, safety and tolerability.

See Also:

The trial is to be conducted in collaboration with the GOG Foundation under a Special Protocol Assessment (SPA) agreement with the FDA and will enrol up to 450 patients at 150 global sites.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last year, the firm reported positive results from the Phase II GOG-0265 trial with better rate of survival in persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC).  

The FDA has granted orphan drug designation and fast track designation for axalimogene filolisbac adjuvant therapy in HRLACC and orphan drug designation for stage II-IV cervical cancer.

The drug was further categorised by the European Medicines Agency's (EMA) as an advanced therapy medicinal product (ATMP) for the treatment of cervical cancer.